subscribeSubscribe
Hepatitis C: Anvisa warns about counterfeit drug

Hepatitis C: Anvisa warns about counterfeit drug
ANVISA
01 Jun 2020
Share Share
AbbVie’s HCV treatment receives first for shorter treatment cycle

AbbVie’s HCV treatment receives first for shorter treatment cycle
B. Hargreaves IN-PHARMATECHNOLOGIST
30 Sep 2019
Share Share
Regulatory barriers limit alternative state drug payment models

Regulatory barriers limit alternative state drug payment models
Samantha Liss BIOSPAHRMADIVE
18 Sep 2019
Share Share
NHS England sees off AbbVie`s Hep C legal challenge

NHS England sees off AbbVie`s Hep C legal challenge
Andrew McCg PM LIVE
22 Jan 2019
Share Share
Supreme Court rebuffs appeals from Merck, Gilead in 2 high-profile drug battles

Supreme Court rebuffs appeals from Merck, Gilead in 2 high-profile drug battles
Arlene Weintraub FIERCE PHARMA
08 Jan 2019
Share Share
AbbVie`s latest hep C push highlights Mavyret`s time-to-cure advantage

AbbVie`s latest hep C push highlights Mavyret`s time-to-cure advantage
Beth S Bulik FIERCE PHARMA
13 Dec 2018
Share Share
What do Martin Shkreli, Gilead and Takeda have in common?

What do Martin Shkreli, Gilead and Takeda have in common?
John Carroll ENDPTS
06 Dec 2018
Share Share
Express Scripts plans `Flex` formulary focused on authorized generics

Express Scripts plans `Flex` formulary focused on authorized generics
Kristin Jensen BIOPHARMA DIVE
14 Nov 2018
Share Share
Merck asks SCOTUS for its $200M in Gilead patent dues

Merck asks SCOTUS for its $200M in Gilead patent dues
Eric Sagonowsky FIERCE PHARMA
26 Sep 2018
Share Share
AbbVie`s facing kickbacks scrutiny with Biogen, Sanofi, Gilead

AbbVie`s facing kickbacks scrutiny with Biogen, Sanofi, Gilead
Eric Sagonowsky FIERCE PHARMA
26 Sep 2018
Share Share